Onsdag 7 Maj | 06:47:07 Europe / Stockholm

Kalender

Est. tid*
2026-02-13 N/A Bokslutskommuniké 2025
2025-11-07 08:50 Kvartalsrapport 2025-Q3
2025-08-22 08:50 Kvartalsrapport 2025-Q2
2025-05-26 N/A X-dag ordinarie utdelning HBC 0.00 NOK
2025-05-23 N/A Årsstämma
2025-05-16 08:50 Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-16 - Kvartalsrapport 2024-Q1
2024-05-13 - X-dag ordinarie utdelning HBC 0.00 NOK
2024-05-10 - Årsstämma
2024-02-09 - Bokslutskommuniké 2023
2024-01-04 - Extra Bolagsstämma 2024
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-05-02 - X-dag ordinarie utdelning HBC 0.00 NOK
2023-04-28 - Årsstämma
2023-02-10 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-30 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-06 - Kvartalsrapport 2022-Q1
2022-05-02 - X-dag ordinarie utdelning HBC 0.00 NOK
2022-04-29 - Årsstämma
2022-02-04 - Bokslutskommuniké 2021
2021-12-03 - Extra Bolagsstämma 2021
2021-11-05 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-21 - Kvartalsrapport 2021-Q1
2021-04-26 - X-dag ordinarie utdelning HBC 0.00 NOK
2021-04-23 - Årsstämma
2021-02-05 - Bokslutskommuniké 2020
2020-11-11 - Extra Bolagsstämma 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-26 - X-dag ordinarie utdelning HBC 0.00 NOK
2020-05-25 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-11-01 - Kvartalsrapport 2019-Q3
2019-08-30 - Extra Bolagsstämma 2019
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-10 - Kvartalsrapport 2019-Q1
2019-04-29 - X-dag ordinarie utdelning HBC 0.00 NOK
2019-04-26 - Årsstämma
2019-02-08 - Bokslutskommuniké 2018
2018-11-02 - Kvartalsrapport 2018-Q3
2018-07-16 - Extra Bolagsstämma 2018
2018-05-09 - Kvartalsrapport 2018-Q1
2018-04-30 - X-dag ordinarie utdelning HBC 0.00 NOK
2018-04-27 - Årsstämma
2018-03-16 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-25 - Årsstämma
2017-05-12 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-18 - Kvartalsrapport 2016-Q3
2016-09-20 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-05-20 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-05-22 - Årsstämma
2015-04-30 - Kvartalsrapport 2015-Q1
2015-03-27 - Bokslutskommuniké 2014
2014-05-02 - Extra Bolagsstämma 2014
2013-12-27 - Extra Bolagsstämma 2013
2013-06-13 - Kapitalmarknadsdag 2013
2012-10-31 - Kvartalsrapport 2012-Q3
2012-08-22 - Kvartalsrapport 2012-Q2
2012-05-25 - Kvartalsrapport 2012-Q1
2012-02-29 - Bokslutskommuniké 2011

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Hofseth BioCare är ett norskt bolag verksamma inom bioteknik. Bolaget utvecklar diverse högkvalitativt protein- och kalciumpulver, samt laxolja. Genom användandet av patenterad teknik kan bolaget i tidigt stadium utvinna ämnen för produktion. Produkterna levereras i form av kosttillskott och säljs via hälsobutiker. Bolaget grundades 2009 och har sitt huvudkontor i Ålesund.
2025-05-05 14:19:41
Nestlé-owned Garden of Life has launched OmeGo® Full Spectrum Omegas on Amazon
in the US. Branded as "Norwegian Salmon Oil", it retains the complete balance
and nutritional profile of fresh Atlantic salmon in a softgel format.

Joining Garden of Life's portfolio of health supplements available online,
Norwegian Salmon Oil containing OmeGo® is gently liberated from fresh, sashimi-
grade salmon and provides whole-fish health benefits from its full spectrum of
omegas. It differentiates from a competitive Omega-3 market that is more focused
on two fatty acids (EPA and DHA). In contrast, OmeGo® is direct and sustainable
from "fjord to shore" and provides Omegas 3, 5, 6, 7, 9 and 11, as well as other
mediators promoting anti-inflammatory and antioxidant benefits to human health.

HBC has recently published scientific findings on the powerful natural anti-
inflammatory benefits of OmeGo® for immune health, allergies and sleep quality
following successful low dose clinical studies.

For further information, please contact:
James Berger, Chief Commercial Officer of Hofseth BioCare ASA
Phone: +41 799501034
E-mail: jb@hofsethbiocare.com

About Hofseth BioCare ASA:

Hofseth BioCare is a Norwegian consumer and pet health company founded on the
core values of sustainability, optimal utilization of natural resources and full
traceability. It upcycles the side streams of the salmon industry by taking
fresh filleted salmon and converting it from a waste product into ingredients to
improve human and pet health. These ingredients are ProGo®, a mix of bioactive
peptides and collagen, OmeGo®, a whole salmon oil, with all the fatty acid
fractions contained in fish, and CalGo® / NT-II(TM) salmon bone powder
containing
calcium hydroxyapatite and undenatured collagen for bone and joint health.

HBC places scientific evidence at the forefront which has led to important
academic partnerships and the identification of unique health benefits. This
includes the demonstration of improved iron metabolism by boosting the body's
ability to take up and use iron resulting in increased energy and vitality with
ProGo® as well as the activation of the GLP-1 receptor with fat reduction in
overweight adults. OmeGo® has shown important immune health benefits including
recovery from viral infection and improved respiratory health and sleep in
adults troubled by particulate matter pollution. Finally, CalGo® has shown both
bone and joint health benefits to support healthy ageing and active lifestyles.
This work has also resulted in the granting of a number of patents protecting
these discoveries. It has also led to the discovery of potential therapeutics
and HBC has spun out a biotech-focused company, HBC Immunology (HBCI). HBCI has
raised external finance, and the lead program is in prostate cancer followed by
ovarian cancer. A separate molecule is targeted as an oral, steroid-sparing
therapy for asthma.